Cargando…

Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China

OBJECTIVE: The study aims to quantify patients’ risk-benefit preferences for chemotherapy in the treatment of non-small cell lung cancer (NSCLC), and to elicit their willingness to pay (WTP) for treatment outcomes. METHODS: A face-to-face discrete choice experiment (DCE) was conducted on NSCLC patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Hui, Wang, Huishan, Xu, Ningze, Li, Junling, Shi, Jufang, Zhou, Naitong, Ni, Ming, Hu, Xianzhi, Chen, Yingyao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790116/
https://www.ncbi.nlm.nih.gov/pubmed/31631985
http://dx.doi.org/10.2147/PPA.S224529
_version_ 1783458746074136576
author Sun, Hui
Wang, Huishan
Xu, Ningze
Li, Junling
Shi, Jufang
Zhou, Naitong
Ni, Ming
Hu, Xianzhi
Chen, Yingyao
author_facet Sun, Hui
Wang, Huishan
Xu, Ningze
Li, Junling
Shi, Jufang
Zhou, Naitong
Ni, Ming
Hu, Xianzhi
Chen, Yingyao
author_sort Sun, Hui
collection PubMed
description OBJECTIVE: The study aims to quantify patients’ risk-benefit preferences for chemotherapy in the treatment of non-small cell lung cancer (NSCLC), and to elicit their willingness to pay (WTP) for treatment outcomes. METHODS: A face-to-face discrete choice experiment (DCE) was conducted on NSCLC patients in four tertiary hospitals each from Beijing, Shanghai, Guangzhou and Chengdu in China. Patients were invited to complete choice questions that constructed by seven attributes: progression-free survival (PFS), disease control rate (DCR), rash, nausea and vomiting, tiredness, mode of administration and out-of-pocket costs. A mixed logit model was used to evaluate the choice model. Estimates of relative preferences and marginal willingness to pay for each attribute were then explored. RESULTS: A total of 361 patients completed the survey. Improvements in PFS (10, 95% CI: 8.4–11.6) were the most important attribute for patients, followed by increase in DCR (4.6, 95% CI: 3.4–5.8). Tiredness (3.9, 95% CI: 2.9–5.1) was judged to be the most important risk. While remaining attributes were ranked in decreasing order of importance: nausea and vomiting (1.9, 95% CI: 0.9–3.0), mode of administration (0.8, 95% CI: 0.2–1.4) and rash (0.5, 95% CI: −0.6–1.5). There was little variation in preferences among patients with different sociodemographic characteristics. Patients were monthly willing to pay $2304 (95% CI, $1916–$2754) that guaranteed 11 months of PFS, followed by $1465 (95% CI, $1163-$1767) per month to improve their disease control rate by 90%. CONCLUSION: The results suggested that efficacy was the most important attribute for patients. Side effects, mode of administration and treatment cost significantly influenced patient preferences. Patient engagement in prioritizing their treatment preferences should be emphasized during the clinical decision-making process and regimen implementation.
format Online
Article
Text
id pubmed-6790116
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67901162019-10-18 Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China Sun, Hui Wang, Huishan Xu, Ningze Li, Junling Shi, Jufang Zhou, Naitong Ni, Ming Hu, Xianzhi Chen, Yingyao Patient Prefer Adherence Original Research OBJECTIVE: The study aims to quantify patients’ risk-benefit preferences for chemotherapy in the treatment of non-small cell lung cancer (NSCLC), and to elicit their willingness to pay (WTP) for treatment outcomes. METHODS: A face-to-face discrete choice experiment (DCE) was conducted on NSCLC patients in four tertiary hospitals each from Beijing, Shanghai, Guangzhou and Chengdu in China. Patients were invited to complete choice questions that constructed by seven attributes: progression-free survival (PFS), disease control rate (DCR), rash, nausea and vomiting, tiredness, mode of administration and out-of-pocket costs. A mixed logit model was used to evaluate the choice model. Estimates of relative preferences and marginal willingness to pay for each attribute were then explored. RESULTS: A total of 361 patients completed the survey. Improvements in PFS (10, 95% CI: 8.4–11.6) were the most important attribute for patients, followed by increase in DCR (4.6, 95% CI: 3.4–5.8). Tiredness (3.9, 95% CI: 2.9–5.1) was judged to be the most important risk. While remaining attributes were ranked in decreasing order of importance: nausea and vomiting (1.9, 95% CI: 0.9–3.0), mode of administration (0.8, 95% CI: 0.2–1.4) and rash (0.5, 95% CI: −0.6–1.5). There was little variation in preferences among patients with different sociodemographic characteristics. Patients were monthly willing to pay $2304 (95% CI, $1916–$2754) that guaranteed 11 months of PFS, followed by $1465 (95% CI, $1163-$1767) per month to improve their disease control rate by 90%. CONCLUSION: The results suggested that efficacy was the most important attribute for patients. Side effects, mode of administration and treatment cost significantly influenced patient preferences. Patient engagement in prioritizing their treatment preferences should be emphasized during the clinical decision-making process and regimen implementation. Dove 2019-10-08 /pmc/articles/PMC6790116/ /pubmed/31631985 http://dx.doi.org/10.2147/PPA.S224529 Text en © 2019 Sun et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sun, Hui
Wang, Huishan
Xu, Ningze
Li, Junling
Shi, Jufang
Zhou, Naitong
Ni, Ming
Hu, Xianzhi
Chen, Yingyao
Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China
title Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China
title_full Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China
title_fullStr Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China
title_full_unstemmed Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China
title_short Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China
title_sort patient preferences for chemotherapy in the treatment of non-small cell lung cancer: a multicenter discrete choice experiment (dce) study in china
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790116/
https://www.ncbi.nlm.nih.gov/pubmed/31631985
http://dx.doi.org/10.2147/PPA.S224529
work_keys_str_mv AT sunhui patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina
AT wanghuishan patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina
AT xuningze patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina
AT lijunling patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina
AT shijufang patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina
AT zhounaitong patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina
AT niming patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina
AT huxianzhi patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina
AT chenyingyao patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina